An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher.
作者信息
Ramachandran Reshma, Gupta Ravi, Luo Jing
机构信息
Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA. Jing Luo is with the Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
出版信息
Am J Public Health. 2021 Nov;111(11):1923-1926. doi: 10.2105/AJPH.2021.306495. Epub 2021 Oct 14.
Abstract
摘要
相似文献
1
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher.给新冠疫苗和治疗药物的一份不必要的礼物：医疗对策优先审评券
Am J Public Health. 2021 Nov;111(11):1923-1926. doi: 10.2105/AJPH.2021.306495. Epub 2021 Oct 14.
2
Pool patents to get COVID vaccines and drugs to all.集中专利，让所有人都能获得新冠疫苗和药物。
Nature. 2021 Mar;591(7851):529. doi: 10.1038/d41586-021-00759-9.
3
Not in my backyard: COVID-19 vaccine development requires someone to be infected somewhere.不要在我家后院发生：新冠疫苗研发需要有人在某个地方被感染。
Med J Aust. 2021 Mar;214(4):150-152.e1. doi: 10.5694/mja2.50930. Epub 2021 Feb 7.
4
How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis.新型 COVID-19 疫苗研发模式如何助力应对史诗级公共卫生危机。
Health Aff (Millwood). 2021 Mar;40(3):410-418. doi: 10.1377/hlthaff.2020.02012. Epub 2021 Feb 4.
5
Don't worry about the drug industry's profits when considering a waiver on covid-19 intellectual property rights.在考虑豁免新冠病毒知识产权时，无需担心制药行业的利润。
BMJ. 2022 Jan 31;376:e067367. doi: 10.1136/bmj-2021-067367.
6
Covid-19: an economic perspective on vaccinating the world.新冠疫情：全球疫苗接种的经济视角
BMJ. 2021 Jun 15;373:n1498. doi: 10.1136/bmj.n1498.
7
Is there light at the end of the Covid-19 tunnel?新冠疫情的隧道尽头会有曙光吗？
Rev Med Virol. 2021 May;31(3):e2173. doi: 10.1002/rmv.2173. Epub 2020 Oct 1.
8
Biopharma dealmaking in 2020.2020年生物制药交易情况。
Nat Rev Drug Discov. 2021 Feb;20(2):95-96. doi: 10.1038/d41573-021-00015-9.
9
The COVID-19 Innovation System.《COVID-19 创新体系》
Health Aff (Millwood). 2021 Mar;40(3):400-409. doi: 10.1377/hlthaff.2020.02097. Epub 2021 Feb 4.
10
Profiteering from vaccine inequity: a crime against humanity?从疫苗不公平中牟取暴利：反人类罪？
BMJ. 2021 Aug 16;374:n2027. doi: 10.1136/bmj.n2027.
引用本文的文献
1
Lessons Learned from Unfettered U.S. Government Support of the NIH-Moderna Vaccine.从美国政府对美国国立卫生研究院-莫德纳疫苗的无限制支持中吸取的教训。
J Law Med Ethics. 2023;51(S2):41-45. doi: 10.1017/jme.2023.155. Epub 2024 Mar 4.
本文引用的文献
1
Origins and Ownership of Remdesivir: Implications for Pricing.瑞德西韦的起源与所有权：对定价的影响。
J Law Med Ethics. 2020 Sep;48(3):613-618. doi: 10.1177/1073110520958890.
2
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
3
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.评估支持美国食品和药物管理局批准新型治疗药物的临床试验，1995-2017 年。
JAMA Netw Open. 2020 Apr 1;3(4):e203284. doi: 10.1001/jamanetworkopen.2020.3284.
4
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
5
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.改良安卡拉牛痘疫苗作为天花疫苗的 3 期疗效试验。
N Engl J Med. 2019 Nov 14;381(20):1897-1908. doi: 10.1056/NEJMoa1817307.
6
The development and approval of tecoviromat (TPOXX), the first antiviral against smallpox.天花病毒的第一种抗病毒药物特考韦瑞（TPOXX）的研发与获批。
Antiviral Res. 2019 Aug;168:168-174. doi: 10.1016/j.antiviral.2019.06.005. Epub 2019 Jun 7.
7
Oral Tecovirimat for the Treatment of Smallpox.口服特考韦瑞玛用于天花的治疗。
N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688.
8
Experience With the Priority Review Voucher Program for Drug Development.药物开发优先审评券计划的经验
JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845.
9
Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths.美国的阿片类药物滥用情况以及美国卫生与公众服务部为应对与阿片类药物相关的过量用药和死亡所采取的行动。
J Pain Palliat Care Pharmacother. 2015 Jun;29(2):133-9. doi: 10.3109/15360288.2015.1037530.
10
Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice.应急准备与响应助理部长办公室；美国卫生与公众服务部针对化学、生物、放射和核威胁的公共卫生应急医疗对策企业实施计划。通知。
Fed Regist. 2007 Apr 23;72(77):20117-28.
Zotero 插件